Johnson & Johnson is trading 3.02% up at $278.15 in after-hours trading after the European Medicines Agency’s CHMP recommended expanding TECVAYLI approval for adults with relapsed or refractory multiple myeloma after at least one prior therapy.
- Positive Phase 3 results supported the recommendation, including a 71% reduction in progression or death risk versus standard care.
- The company-specific regulatory catalyst likely explains the after-hours jump; broader market support was secondary.